These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2028446)

  • 21. Inhibition of activated protein C by benzamidine derivatives.
    Stürzebecher J; Prasa D; Taby O
    Thromb Res; 1993 Mar; 69(6):533-9. PubMed ID: 8503121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A screening procedure to evaluate the anticoagulant activity and the kinetic behaviour of direct thrombin inhibitors.
    Rupin A; Mennecier P; de Nanteuil G; Laubie M; Verbeuren TJ
    Thromb Res; 1995 May; 78(3):217-25. PubMed ID: 7631302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological characterization of a new highly effective synthetic thrombin inhibitor.
    Kaiser B; Hauptmann J; Weiss A; Markwardt F
    Biomed Biochim Acta; 1985; 44(7-8):1201-10. PubMed ID: 4084272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats.
    Furugohri T; Fukuda T; Tsuji N; Kita A; Morishima Y; Shibano T
    Eur J Pharmacol; 2012 Jul; 686(1-3):74-80. PubMed ID: 22546231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation and evaluation of PEG-bound thrombin inhibitors based on 4-amidinophenylalanine.
    Stüber W; Koschinsky R; Reers M; Hoffmann D; Czech J; Dickneite G
    Pept Res; 1995; 8(2):78-85. PubMed ID: 7655188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The design of phenylglycine containing benzamidine carboxamides as potent and selective inhibitors of factor Xa.
    Jones SD; Liebeschuetz JW; Morgan PJ; Murray CW; Rimmer AD; Roscoe JM; Waszkowycz B; Welsh PM; Wylie WA; Young SC; Martin H; Mahler J; Brady L; Wilkinson K
    Bioorg Med Chem Lett; 2001 Mar; 11(5):733-6. PubMed ID: 11266180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein-Templated Formation of an Inhibitor of the Blood Coagulation Factor Xa through a Background-Free Amidation Reaction.
    Jaegle M; Steinmetzer T; Rademann J
    Angew Chem Int Ed Engl; 2017 Mar; 56(13):3718-3722. PubMed ID: 28199769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.
    Olah Z; Szarvas M; Bereczky Z; Kerenyi A; Kappelmayer J; Boda Z
    Arch Pathol Lab Med; 2013 Jul; 137(7):967-73. PubMed ID: 23808469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.
    Adcock DM; Gosselin R
    Thromb Res; 2015 Jul; 136(1):7-12. PubMed ID: 25981138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are factor Xa inhibitors superior to thrombin inhibitors in anticoagulation?
    Stürzebecher J; Stürzebecher U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):152-6. PubMed ID: 2459011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver. Interaction with bile acid transport systems.
    Eckhardt U; Stüber W; Dickneite G; Reers M; Petzinger E
    Biochem Pharmacol; 1996 Jul; 52(1):85-96. PubMed ID: 8678912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HPLC Determination of the synthetic thrombin inhibitor N alpha-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide in biological material.
    Paintz M; Richter M; Hauptmann J
    Pharmazie; 1987 May; 42(5):346. PubMed ID: 3671450
    [No Abstract]   [Full Text] [Related]  

  • 33. Kinetic studies on the selectivity of a synthetic thrombin-inhibitor using synthetic peptide substrates.
    Hijikata A; Okamoto S; Kikumoto R; Tamao Y
    Thromb Haemost; 1979 Oct; 42(3):1039-45. PubMed ID: 159513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo comparison of arginine- and benzamidine-derived highly potent synthetic thrombin inhibitors.
    Hauptmann J; Kaiser B
    Pharmazie; 1991 Jan; 46(1):57-8. PubMed ID: 1857734
    [No Abstract]   [Full Text] [Related]  

  • 35. Aromatic amidines: inhibitory effect on purified plasma serine proteinases, blood coagulation and platelet aggregation.
    Ferroni R; Menegatti E; Guarneri M; Taddeo U; Ascenzi P; Amiconi G
    Farmaco Sci; 1988 Jan; 43(1):5-13. PubMed ID: 3165070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Use of synthetic inhibitors in coagulation physiological tests with peptide substrates].
    Stürzebecher J; Klessen C
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):157-60. PubMed ID: 6177597
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors.
    Hauptmann J; Kaiser B; Nowak G; Stürzebecher J; Markwardt F
    Thromb Haemost; 1990 Apr; 63(2):220-3. PubMed ID: 2363124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.
    Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y
    Eur J Pharmacol; 1998 Apr; 347(2-3):231-6. PubMed ID: 9653887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of benzamidine-type inhibitors of factor Xa.
    Gabriel B; Stubbs MT; Bergner A; Hauptmann J; Bode W; Stürzebecher J; Moroder L
    J Med Chem; 1998 Oct; 41(22):4240-50. PubMed ID: 9784099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.